Latest From Abbisko Therapeutics
Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.
UK pharma giant’s head, International tells Scrip expanded alliance with diversified Japan group will develop solutions across the patient journey, while new China investments aim to tap into emerging innovation in this market.
The past few months have seen frenzied venture capital and other investment in the Chinese pharma and biotech space, driven by increasingly innovative startups run by big pharma veterans, while corporate ventures have been joining with private equity to build up specialist investment and M&A funds.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
- Therapeutic Areas
- Parent & Subsidiaries
- Abbisko Therapeutics
- Senior Management
Yaochang Xu, PhD, CEO
Kathy He, VP, Corp. & Bus. Dev.
Wang Yu, MD, PhD, CMO
- Contact Info
Phone: 21 68912098
Bldg. 3, No. 898, Halei Rd.